# Trevi Therapeutics, Inc.: financial statements, quarterly

TRVI · Nasdaq · CIK 1563880 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/trvi.md) · [Financials](/companies/trvi/financials.md) · [Filings](/companies/trvi/filings.md) · [Insiders](/companies/trvi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/trvi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [6.3](/filings/0000950170-24-122355.md) | [6.5 d](/filings/0000950170-25-041194.md) | [8.8](/filings/0000950170-25-067011.md) | [10.0](/filings/0000950170-25-105066.md) | [11.2](/filings/0001193125-25-280166.md) | [9.3 d](/filings/0001193125-26-110783.md) | [7.8](/filings/0001193125-26-206390.md) | [9.4](/filings/0001193125-26-338023.md) | [10.1](/filings/0001193125-25-280166.md) | [6.2 d](/filings/0001193125-26-110783.md) | [9.9](/filings/0001193125-26-206390.md) | [15.2](/filings/0001193125-26-338023.md) |
| Operating income | $m | [(9.0)](/filings/0000950170-24-122355.md) | [(8.9) d](/filings/0000950170-25-041194.md) | [(11.9)](/filings/0000950170-25-067011.md) | [(13.3)](/filings/0000950170-25-105066.md) | [(14.1)](/filings/0001193125-25-280166.md) | [(12.2) d](/filings/0001193125-26-110783.md) | [(11.5)](/filings/0001193125-26-206390.md) | [(13.7)](/filings/0001193125-26-338023.md) | [(13.9)](/filings/0001193125-25-280166.md) | [(10.2) d](/filings/0001193125-26-110783.md) | [(14.9)](/filings/0001193125-26-206390.md) | [(20.5)](/filings/0001193125-26-338023.md) |
| Interest expense | $m | [0.0](/filings/0000950170-23-062063.md) | [0.0 d](/filings/0000950170-24-034167.md) | [0.0](/filings/0000950170-24-054489.md) | [0.0](/filings/0000950170-24-093983.md) | [0.0](/filings/0001193125-25-280166.md) | [0.0 d](/filings/0001193125-26-110783.md) | not reported | [0.0](/filings/0000950170-25-105066.md) | [0.0](/filings/0001193125-25-280166.md) | [0.0 d](/filings/0001193125-26-110783.md) | not reported | not reported |
| Income tax | $m | [(0.0)](/filings/0000950170-24-122355.md) | [0.0 d](/filings/0000950170-25-041194.md) | [(0.0)](/filings/0000950170-25-067011.md) | [(0.0)](/filings/0000950170-25-105066.md) | [(0.0)](/filings/0001193125-25-280166.md) | [0.0 d](/filings/0001193125-26-110783.md) | [(0.0)](/filings/0001193125-26-206390.md) | [(0.0)](/filings/0001193125-26-338023.md) | [(0.0)](/filings/0001193125-25-280166.md) | [(0.0) d](/filings/0001193125-26-110783.md) | [(0.0)](/filings/0001193125-26-206390.md) | [(0.0)](/filings/0001193125-26-338023.md) |
| Net income | $m | [(7.7)](/filings/0000950170-24-122355.md) | [(7.8) d](/filings/0000950170-25-041194.md) | [(10.9)](/filings/0000950170-25-067011.md) | [(12.4)](/filings/0000950170-25-105066.md) | [(13.2)](/filings/0001193125-25-280166.md) | [(11.4) d](/filings/0001193125-26-110783.md) | [(10.3)](/filings/0001193125-26-206390.md) | [(12.3)](/filings/0001193125-26-338023.md) | [(11.8)](/filings/0001193125-25-280166.md) | [(8.3) d](/filings/0001193125-26-110783.md) | [(13.2)](/filings/0001193125-26-206390.md) | [(17.8)](/filings/0001193125-26-338023.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0000950170-24-122355.md) | not reported | [(0.11)](/filings/0000950170-25-067011.md) | [(0.12)](/filings/0000950170-25-105066.md) | [(0.13)](/filings/0001193125-25-280166.md) | not reported | [(0.09)](/filings/0001193125-26-206390.md) | [(0.09)](/filings/0001193125-26-338023.md) | [(0.08)](/filings/0001193125-25-280166.md) | not reported | [(0.09)](/filings/0001193125-26-206390.md) | [(0.11)](/filings/0001193125-26-338023.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0000950170-24-122355.md) | not reported | [(0.11)](/filings/0000950170-25-067011.md) | [(0.12)](/filings/0000950170-25-105066.md) | [(0.13)](/filings/0001193125-25-280166.md) | not reported | [(0.09)](/filings/0001193125-26-206390.md) | [(0.09)](/filings/0001193125-26-338023.md) | [(0.08)](/filings/0001193125-25-280166.md) | not reported | [(0.09)](/filings/0001193125-26-206390.md) | [(0.11)](/filings/0001193125-26-338023.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [26.0](/filings/0000950170-23-062063.md) | [32.4](/filings/0000950170-25-041194.md) | [13.8](/filings/0000950170-24-054489.md) | [13.0](/filings/0000950170-24-093983.md) | [16.1](/filings/0000950170-24-122355.md) | [34.1](/filings/0001193125-26-110783.md) | [19.4](/filings/0000950170-25-067011.md) | [117](/filings/0000950170-25-105066.md) | [56.9](/filings/0001193125-25-280166.md) | [18.9](/filings/0001193125-26-338023.md) | [19.4](/filings/0001193125-26-206390.md) | [54.3](/filings/0001193125-26-338023.md) |
| Current assets | $m | [94.0](/filings/0000950170-23-062063.md) | [87.5](/filings/0000950170-25-041194.md) | [76.8](/filings/0000950170-24-054489.md) | [72.1](/filings/0000950170-24-093983.md) | [67.3](/filings/0000950170-24-122355.md) | [109](/filings/0001193125-26-110783.md) | [106](/filings/0000950170-25-067011.md) | [207](/filings/0000950170-25-105066.md) | [198](/filings/0001193125-25-280166.md) | [192](/filings/0001193125-26-338023.md) | [176](/filings/0001193125-26-206390.md) | [326](/filings/0001193125-26-338023.md) |
| Total assets | $m | [95.9](/filings/0000950170-23-062063.md) | [89.4](/filings/0000950170-25-041194.md) | [78.6](/filings/0000950170-24-054489.md) | [73.8](/filings/0000950170-24-093983.md) | [68.9](/filings/0000950170-24-122355.md) | [111](/filings/0001193125-26-110783.md) | [107](/filings/0000950170-25-067011.md) | [208](/filings/0000950170-25-105066.md) | [199](/filings/0001193125-25-280166.md) | [193](/filings/0001193125-26-338023.md) | [180](/filings/0001193125-26-206390.md) | [331](/filings/0001193125-26-338023.md) |
| Current liabilities | $m | [5.2](/filings/0000950170-23-062063.md) | [5.8](/filings/0000950170-25-041194.md) | [5.3](/filings/0000950170-24-054489.md) | [6.8](/filings/0000950170-24-093983.md) | [9.1](/filings/0000950170-24-122355.md) | [10.5](/filings/0001193125-26-110783.md) | [6.9](/filings/0000950170-25-067011.md) | [9.2](/filings/0000950170-25-105066.md) | [9.0](/filings/0001193125-25-280166.md) | [9.7](/filings/0001193125-26-338023.md) | [7.1](/filings/0001193125-26-206390.md) | [8.7](/filings/0001193125-26-338023.md) |
| Total liabilities | $m | [6.3](/filings/0000950170-23-062063.md) | [6.9](/filings/0000950170-25-041194.md) | [6.2](/filings/0000950170-24-054489.md) | [7.6](/filings/0000950170-24-093983.md) | [9.9](/filings/0000950170-24-122355.md) | [11.3](/filings/0001193125-26-110783.md) | [7.5](/filings/0000950170-25-067011.md) | [9.8](/filings/0000950170-25-105066.md) | [9.6](/filings/0001193125-25-280166.md) | [10.2](/filings/0001193125-26-338023.md) | [7.5](/filings/0001193125-26-206390.md) | [9.0](/filings/0001193125-26-338023.md) |
| Shareholders' equity | $m | [89.6](/filings/0000950170-24-122355.md) | [82.5](/filings/0001193125-26-110783.md) | [72.3](/filings/0000950170-25-105066.md) | [66.2](/filings/0001193125-25-280166.md) | [59.0](/filings/0001193125-25-280166.md) | [99.6](/filings/0001193125-26-338023.md) | [99.5](/filings/0001193125-26-338023.md) | [198](/filings/0001193125-26-338023.md) | [190](/filings/0001193125-25-280166.md) | [183](/filings/0001193125-26-338023.md) | [172](/filings/0001193125-26-338023.md) | [322](/filings/0001193125-26-338023.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.3) d](/filings/0000950170-24-122355.md) | [(6.4) d](/filings/0000950170-25-041194.md) | [(10.5)](/filings/0000950170-25-067011.md) | [(8.7) d](/filings/0000950170-25-105066.md) | [(9.6) d](/filings/0001193125-25-280166.md) | [(9.6) d](/filings/0001193125-26-110783.md) | [(13.5)](/filings/0001193125-26-206390.md) | [(10.1) d](/filings/0001193125-26-338023.md) | [(10.9) d](/filings/0001193125-25-280166.md) | [(7.6) d](/filings/0001193125-26-110783.md) | [(16.7)](/filings/0001193125-26-206390.md) | [(17.4) d](/filings/0001193125-26-338023.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-122355.md) | [0.0 d](/filings/0000950170-25-041194.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-280166.md) | [0.0 d](/filings/0001193125-26-110783.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-280166.md) | [0.0 d](/filings/0001193125-26-110783.md) | [0.1](/filings/0001193125-26-206390.md) | [0.1 d](/filings/0001193125-26-338023.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [68.9](/filings/0000950170-23-062063.md) | [98.6](/filings/0000950170-24-054489.md) | [98.7](/filings/0000950170-24-093983.md) | [99.3](/filings/0000950170-24-122355.md) | [99.5](/filings/0000950170-25-067011.md) | [101](/filings/0000950170-25-105066.md) | [101](/filings/0001193125-25-280166.md) | [118](/filings/0001193125-26-206390.md) | [130](/filings/0001193125-26-338023.md) | [145](/filings/0001193125-25-280166.md) | [146](/filings/0001193125-26-206390.md) | [157](/filings/0001193125-26-338023.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 142,475,841 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338023.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.